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Introduction
Contrast media (CM) enhance the quality of images, revo-
lutionizing the radiologist’s ability to differentiate soft-
tissue densities. Ideally, CM should achieve very high 
concentration in the tissues without producing any adverse 
effects. Unfortunately this has not been possible so far and 
all CM have adverse effects [1].
In the last decades procedures employing CM have rapidly 
increased. Significant improvements in the composition of 
CM during the past few decades have made them safer and 
better tolerated. Nonetheless, risks associated with CM have 
not been eliminated: varying degrees of adverse reactions con-
tinue to occur, and, in some situations, their use is problem-
atic [2–7]. The reported rates of severe reactions to CM are 
quite low; however they can quickly became life-threatening 
and lead to death [8–11]. Radiologists have been challenged in 
many ways by the issues arising from the increasingly wide-
spread use of CM. The aim of this review is to define those 
medico-legal issues we believe to be most pertinent to the use 
of CM in diagnostic imaging as we know it today.
Informed consent
The basic concept of informed consent is familiar to radi-
ologists [12, 13]; radiologists are aware that no diagnostic 
investigation can be performed without the patient’s valid 
consent and that the patient must be given adequate infor-
mation and sufficient data to be able to make an informed 
decision about the examination. However, failure to obtain 
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proper informed consent is a frequent cause of lawsuits. A 
recent United States nationwide research showed that the 
commonest causes of medical malpractice suits against 
radiologists were diagnostic errors and procedural compli-
cations, followed by inadequate communication with either 
patient or referring physician [14]. Data coming from Euro-
pean countries confirmed that lack or invalidity of informed 
consent is highly problematic in radiological practice [15–
17]. Interestingly, O’Dwyer et al. [17] reported that more 
than 50 % of the radiologists interviewed were unhappy 
with their policies for obtaining informed consent.
Effective physician–patient communication is an endur-
ing process. Consent to medical intervention infers a pro-
found relationship between patient and physician which 
cannot be compressed into a short encounter. It is a pro-
cess which implies the doctor’s duty to inform patients of 
the benefits and potential risks of the treatment options, to 
answer their questions openly and honestly, to help patients 
in their choice and, finally, to accept that choice [18].
Special scenarios and caveats regarding the practice 
of radiology and particularly the use of CM need to be 
discussed.
One key question is that the patient-radiologist relation-
ship tends to be brief and episodic, so that radiologists are 
unlikely to have an established relationship with the patient 
[19], and may not feel comfortable discussing the risks and 
complications of their procedures with the patient [20]. 
Undoubtedly, time is a critical issue for radiologists in the 
informed consent process [21, 22]. In their survey on cur-
rent European practice, O’Dwyer et al. [17] report that, 
despite the fact the appropriate time for obtaining informed 
consent is considered to be more than 24 h prior to the pro-
cedure, very often it is obtained on the same morning or 
immediately before the procedure itself. However, patients 
have to be provided with adequate time to consider the 
information they have received. Finally, also the time that 
radiologists spend with patients is critical in ensuring that 
patients are satisfactorily informed [23].
Another key point is the amount of information, espe-
cially with regard to risks, that should be given to patients; 
and in radiological practice the use of CM exacerbates the 
issue [24–26]. The appropriateness of the use of CM, any 
alternative procedure, the risks and benefits of not under-
going the proposed diagnostic or interventional procedure 
with CM have to be outlined in the informative process. On 
exploring patients’ attitude towards informed consent for 
CM, Hopper et al. [27] pointed out that most people desire 
to be informed before a contrast injection. It is generally 
argued that excessive and detailed information about the 
risks of the procedure may increase the levels of anxiety in 
a patient awaiting administration of CM. On the contrary, 
balanced communication about the risks seems to reduce 
anxiety levels [28–30]. In the ACR manual on CM [13] it 
is stated that ‘because of the documented low incidence of 
adverse events, intravenous injection of contrast media may 
be exempted from the need for informed consent, but this 
decision should be based on state law, institutional policy, 
and departmental policy’. Other authors seem to take the 
same view [31].
Contrarily, we believe that the low statistical frequency 
of complications, specifically those which are life-threaten-
ing, does not exempt radiologists from the duty to inform 
patients of these specific risks. Obtaining consent for all 
radiological CM procedures is an ethical duty, regardless of 
the nature of the agent used and the incidence and severity 
of the possible adverse events. A correct informative pro-
cess is one in which physicians communicate the gist of the 
message to the patients, i.e., that there is some risk involved 
in the use of CM. Communicating the gist without referring 
to statistics, tailoring information to the patient’s needs and 
facilitating people’s understanding are essential elements 
of informed consent when radiologists are using contrast 
agents.
Finally, the form of informed consent (written or ver-
bal) that is mainly based on state laws, and institutional 
and departmental policies. Some general considerations 
on the form of communication can be of interest. Efforts 
to improve information delivery and patient knowledge are 
widely reported in the literature as an important prerequi-
site for informed consent. There is wide agreement that a 
multimedia approach combining videos, verbal communi-
cation, audio tape, pamphlets, and interactive methods of 
communication may improve the patient’s comprehension 
and participation in the decision-making process [32]. The 
readability of informed consent forms is a critical issue 
[33] as many informative leaflets are written in such a way 
as to be incomprehensible to the average patient.
The above-mentioned criticisms arise particularly in 
emergencies where an inherent difficulty with obtaining 
adequate informed consent exists [34, 35].
Off‑label use
The first point concerns the definition of off-label contrast 
medium (OLCM) which depends on the regulatory envi-
ronment of different countries. In general terms, off-label 
use means use other than the originally tested and licenced 
indications, and the obtaining of licences depends on drug 
laws which may vary from country to country.
In the European normative framework, CM fall within the 
definition of medicinal product (EC Directive 2004/27/EC 31 
March 2004): ‘Any substance or combination of substances 
which may be used in or administered to human beings either 
with a view to restoring, correcting or modifying physiological 
functions by exerting a pharmacological, immunological or 
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metabolic action, or to making a medical diagnosis’ [36, 37]. 
In the United States off-label use generally means that a medi-
cal product is not administered for the specific use approved 
by the food and drug administration (FDA) and listed in the 
drug-labelling information. To sum up, off-label use of a 
medical product is its prescription and use in a manner and for 
purposes other than those approved by competent authoritative 
agencies and national drug laws. Since these agencies regulate 
only the labelling of the medical products and do not regulate 
the practice of medicine, the off-label use of drugs and medi-
cal products is becoming increasingly common [38].
To fully understand the medico-legal implications 
of OLCM, the differences existing between CM and 
other drugs have to be taken into account. As outlined by 
Thomsen in his editorial, CM “are not designed to have 
therapeutic effects and they are administered in one dose, 
under medical supervision, and provide their effect under 
the principles of physics, not those of pharmacology” 
[39]. According to current regulations CM are officially 
approved for some specific uses and for body areas; their 
use in imaging the rest of the body is considered “off-label” 
[39]. For all these reasons, often the approved indications 
do not match the real clinical and diagnostic needs and in 
daily practice the off-label use of the CM is extremely com-
mon, mostly involving gadolinium-based contrast agents 
(GBCAs), especially in MR angiography, cardiac and pae-
diatric applications [36, 40].
The most striking example is contrast-enhanced ultra-
sound (CEUS), particularly in the paediatric population, 
that is increasingly practised since it may reduce the use 
of ionizing radiations, and nowadays it is an established 
technique for many organs. In Europe, the use of CEUS 
is approved for a limited number of indications in adults 
[41]. Cardiac application of ultrasound contrast agent is 
approved in the United States, but it is not known when or 
if ultrasound contrast agents will be approved for non-car-
diac applications there [42]. No-labelled use is approved in 
the paediatric population [43]. There is widespread use in 
Europe [44], and there are ongoing efforts by the Society 
for Paediatric Radiology and International Contrast Ultra-
sound Society to push for paediatric CEUS in the United 
States [45]. Therefore it may be expected that CEUS will 
be increasingly used throughout childhood [46].
Liability profiles may result from OLCM use since, 
despite widespread clinical practice, it is still formally 
outside the regulatory boundaries [37]. This incurs greater 
risks for the radiologist. It is known, for example, that 
with increasing off-label use, significant differences have 
not been observed in the incidence of severe adverse reac-
tions between approved and unapproved use of CM [39]. 
Nevertheless, in the case of adverse reaction, especially if 
severe and life-threatening, the radiologist must demon-
strate that the off-label use of that CM was fully supported 
by scientifically valid evidence and that there were no con-
traindications for the safety of the patient. This is a gen-
eral requirement in off-label use of medical products which 
sharpens the need for strong scientific support for this 
practice. Making a clear distinction between CM off-label 
uses that are well supported by the best scientific evidence 
available and those that are not is the Gordian knot of the 
issue [47]. This concept is strongly supported by the state-
ments of many scientific societies and regulatory bureaus. 
The FDA states that if a physician uses an off-label drug or 
medical device, he or she should base judgment on sound 
medical evidence and should maintain a record of the prod-
ucts used and their effects [48]. In a similar vein is the posi-
tion of the Society of Interventional Radiology which sup-
ports the lawful use by a physician of a drug product for 
an unlabelled indication when such use is based on sound 
scientific evidence and/or sound medical opinion [49]. The 
second vital point, again with regard to the professional 
responsibility of the radiologist and possible requests for 
damages arising from the off-label use of the CM, is the 
information supplied to the patient prior to doing the exam. 
Since the radiologist uses a CM which the regulatory body 
has not stated is safe and effective for that specific use, we 
believe that he/she is obliged to provide exhaustive infor-
mation to patients and obtain formal consent before using 
an OLCM. Conflicting conceptual positions arise around 
the thorny issue of informed consent in the off-label use of 
medical products. Some authors agree that it is not accept-
able for a physician to neglect to tell patients of a medical 
product’s off-label status while some others have contended 
that off-label status is irrelevant to the actual medical risks 
posed [50–52]. While aware of the specific nature of the 
CM with regard to traditional medicines, we consider that 
the radiologist is still obliged to inform the patient of the 
off-label use of the CM, to explain the clinical and scien-
tific reasons supporting it, to highlight the advantages in 
terms of effective diagnosis, to explain any alternative diag-
noses and finally to obtain informed consent to the off-label 
use of the CM [40].
In conclusion, some key points can be drawn. If radiolo-
gists use a contrast agent for non-approved purposes, they 
are responsible for balancing the benefits and the poten-
tial negative effects of such use. They must also base its 
use on firm scientific rationale and on sound medical evi-
dence when alternative labelled products are not of equally 
proven efficacy, and fully inform patients of the potential 
adverse effects of the product.
Finally, it should also be pointed out that it is the duty of 
radiologists to report any suspect adverse reaction associ-
ated with OLCM use to local/national authorities respon-
sible for drug safety monitoring. Radiologists should be 
made aware that the reason for collecting information on 
OLCM use is to ensure the highest standard of patient 
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safety, possibly further to a review by ‘ad hoc’ local and 
national committees of incidents involving OLCM use and 
to subsequent appropriate actions.
Medical liability
The principles regulating medical liability differ from 
country to country and between common law and civil law 
systems, and malpractice in radiology varies across the 
globe [53]. Overall, the percentage of medical malpractice 
lawsuits involving radiologists has been estimated to range 
from 5 to 12 % [54, 55]. Diagnosis seems to be the major 
pitfall for radiologists [14]. In daily practice, around 3–5 % 
of radiological analyses contain errors [56–60]; errors in 
interventional procedures and adverse events occurring 
during a radiological examination take second place in this 
negative ranking [61].
The issue of medical liability and malpractice is not 
unique to radiologists; however, some key points have to 
be stressed, focusing particularly on the use of CM [2, 3, 
62, 63].
Indication for the examination, and specifically the use 
of contrast media
Except for screening tests, radiologists generally receive 
the requests for examination from a referring physician. 
The decision of whether or not to conduct the examination 
and whether CM should be used is left to the radiologist 
[63]. Radiologists may fail to adequately check the appro-
priateness of the indication for the use of CM and to weigh 
up the diagnostic/therapeutic benefits and the possible 
risks. Existing guidelines may strongly assist the radiolo-
gist in making the most appropriate imaging decision for a 
specific patient [64, 65].
Investigation into medical history
Careful investigation into the patient’s medical history 
with special attention to eventual previous reaction to 
CM is critical. The radiologist who decides to use a con-
trast agent should investigate whether the patient has had 
a history of allergy and elicit from the patient any infor-
mation regarding allergies through specific questions 
rather than simply relying on the patient, for the latter 
could overlook clinical significant details (i.e., previous 
life-threatening reaction, episodes of bronchospasm or 
asthma, hypotension or shock from an underlying illness, 
history of allergies, and other medical conditions, includ-
ing possible renal impairment, heart failure, diabetes, 
hyperthyroidism, drug addiction, etc.) [65]. It is notewor-
thy that risk is increased sixfold by a history of adverse 
reaction, six to tenfold by asthma, and to a considerable 
extent by a history of allergic reactions to other drugs 
[66, 67].
Careful attention to special populations
Even more attention is required before administering CM 
to special populations.
Pregnant and breastfeeding women
Beyond the risks related to the exposure of the foetus to 
ionizing radiations and high magnetic fields, the adminis-
tration of CM may be a further hazard for the foetuses and 
neonates [68].
CM cross the human placenta, thus entering the foe-
tus. They can also be secreted into milk during lactation. 
Mutagenic effects have not been described after adminis-
tration of gadolinium or iodinated CM [68–70]. However, 
the lack of adequate and well-controlled studies regard-
ing these possible effects in humans has induced the ACR 
to recommend the use of iodinate-contrast media in preg-
nant women only when: ‘(1) the information requested 
cannot be acquired without contrast administration. (2) 
The information needed affects the care of the patient 
and foetus during the pregnancy. (3) The referring phy-
sician is of the opinion that it is not prudent to wait to 
obtain this information until after the patient is no longer 
pregnant’ [64]. The same caution is required when decid-
ing to use GBCAs. Also, the updated version of ESUR 
guidelines [65] recommends that the use of iodine-based 
CM in pregnant women should be limited only to excep-
tional circumstances and that following their administra-
tion, thyroid function should be checked in the neonate 
during the first week. Regarding the use of gadolinium-
based contrast agents, the revised guidelines recommend 
the administration of the smallest possible dose of the 
most stable GBCAs only when there is a very strong 
indication.
Both iodinate- and gadolinium-based CM are thought to 
be safe for mothers and children. However, full information 
about the mother with regard to the possibility of temporar-
ily stopping lactation is suggested [13]. ESUR guidelines 
state that ‘breast feeding may be continued normally when 
iodine-based agents are given to the mother. Breast feeding 
should be avoided for 24 h after contrast medium if high 
risk agents are used’ [65]. A recent position paper of the 
Italian Society of Radiology, the Italian Society of Paediat-
rics, the Italian Society of Neonatology and the task force 
on breastfeeding, Italian Ministry of Health [71] states that 
‘breastfeeding is safe for the nursing infant of any post-
conceptional age after administration to the mother of all 
iodine-based contrast media and most gadolinium-based 
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contrast media. As a precaution, gadolinium-based agents 
considered at high risk of nephrogenic systemic fibrosis 
should be avoided in the breastfeeding woman. There is 
no need to discontinue breastfeeding for 12–48 h after the 
administration of contrast media and no use in expressing 
and discarding breast milk following the imaging’.
In conclusion, although the regulatory statements and 
clinical practice for the use of contrast media in pregnancy 
and lactation differ [70], caution is strongly advised and 
radiologists must be aware that the use of contrast media 
in pregnant women must be limited to cases when the ben-
efits outweigh the potential risks. Accurate information 
and written informed consent to the procedure are strongly 
advised.
Patients who take metformin
They need special attention before the administration of 
CM since their use, and specifically iodine-based CM, 
may increase the risk of lactic acidosis patients taking met-
formin with known, borderline, or incipient renal dysfunc-
tion [72]. Management varies according to the recurrence 
and/or severity of renal impairment: no discontinuation of 
metformin nor creatinine control in patients with normal 
renal function and no comorbidities is required; discontinu-
ation at the time of examination and for 48 h in patients 
with multiple comorbidities and apparently normal renal 
function, followed by the reassessment of renal function 
before restarting metformin is required. In patients with 
renal dysfunction, metformin should be suspended at the 
time of the contrast injection, and cautious follow-up of 
renal function should be performed until safe reinstitution 
of metformin can be assured. It is not necessary to discon-
tinue metformin prior to gadolinium-enhanced MR when 
the amount of gadolinium administered is in the usual dose 
range [64]. Taking the same view, ESUR guidelines advo-
cate increased attention depending on the existence and 
severity of renal failure for iodinate CM. No special pre-
cautions are requested for GBCAs [65].
Patients with previous renal insufficiency
They are at greater risk of developing contrast-induced 
nephropathy (CIN) than patients whose function is nor-
mal. CIN is a well-described iatrogenic effect of the use 
of iodinate-contrast medium that occurs more frequently 
in patients with previous renal insufficiency [73]. These 
patients deserve special attention in the decision-making 
process leading to the use of CM. Radiologists must be 
fully informed and must use evidence-based protocols [74]. 
Statements from scientific associations provide specific rec-
ommendations on how to manage these patients [64, 65].
Premedication
Premedication is critical in possible liability scenarios 
linked to the use of CM. In some circumstances premedi-
cation is required. We refer to patients with previous reac-
tions to CM for whom a pre-treatment regimen, including 
administration of corticosteroids with or without antihista-
mines or other medications, is thought to be safe. However, 
acute adverse reactions (breakthrough adverse reactions) 
are known to occur even when the patient is pre-medicated 
[75–77]. A recent review of the existing literature shows 
that in unselected patients, the usefulness of premedication 
is doubtful, and data supporting the use of premedication 
in patients with a history of allergic reactions are lacking 
[78]. Local institutional policies may exclude the use of 
CM in patients with prior moderate or severe reactions and 
in pre-medicated patients whose previous reactions were 
mild [77]; however, the Contrast Media Safety Committee 
of ESUR considers the use of premedication, although evi-
dence of its effectiveness is limited in patients with previ-
ous moderate or severe acute reactions [65].
Several different premedication regimens have been pro-
posed to reduce the frequency and/or severity of reactions 
to contrast media. The possible switch to other contrast 
agents, and the strict observation of the patients (20/30 min 
after the contrast medium injection, having drugs and 
equipment for resuscitation quickly and readily available) 
are also suggested as precautions for radiologists [79]. 
However, radiologists are reminded that they should be pre-
pared to deal with the possible reactions [64, 65].
In conclusion, the take-home message is that radiolo-
gists must be wary of reactions in patients with a previ-
ous history of life-threatening reaction, bronchospasm 
or asthma, hypotension or shock from an underlying ill-
ness and allergies and be aware that premedication does 
not completely eliminate the risks of severe and life-
threatening reactions in those patients. Staying alert and 
adequately prepared to administer resuscitation and sup-
portive treatments are essential and cannot be replaced 
by premedication [76, 78]. The statement that ‘physicians 
who are dealing with these patients should not rely on the 
efficacy of premedication’ [78] must be kept in mind by 
radiologists when deciding whether or not to use CM in 
patients with prior reaction.
Appropriateness and timeliness of adverse reaction 
management
Finally, radiologists can be sued if the management of the 
adverse reaction induced by a contrast agent is not prompt 
and correct. Rapid identification of alarming, life-threat-
ening symptoms and adequate therapeutic strategies are 
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recommended according to the kind and the severity of 
the adverse reaction [80, 81]. However, knowledge of the 
management of acute contrast reactions is lacking among 
radiologists [82] and training and educational programmes 
are of paramount importance to help them to improve their 
performance in emergency scenarios following the admin-
istration of CM [82, 83].
Conclusions
The increasing use of CM is likely to give rise to a wide 
range of pitfalls, from compliance with and appropriateness 
of indications, to the choice of the ‘best’ contrast agent. 
Moreover, off-label use, evaluation of special populations 
of patients, and readiness to deal with emergency scenarios 
following the administration of CM are some of the most 
challenging issues for radiologists. Even more prominent, 
and potentially more important, is the issue of informed 
consent which implies a duty to inform patients awaiting 
the administration of CM of the nature of the procedure, 
the existence of alternative procedures, the extent of the 
risks related to their use and, finally, the risks of refusing 
the procedure.
All the above-mentioned issues may give rise to con-
cerns about liability for failure to offer adequate information 
to patients or to carefully evaluate and balance the potential 
risks and benefits of the procedure or, finally, for being unpre-
pared in the event of adverse reactions to CM, especially 
when severe and life-threatening. Educational and training 
programmes for radiologists are likely to shape change in the 
medical liability environment in the years to come.
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